Discovery, characterization, and clinical development of the glucagon-like peptides

Journal of Clinical Investigation

Volumn 127, Issue 12, 2017, Pages 4217-4227

  Drucker, Daniel J ^a   Habener, Joel F ^b   Holst, Jens Juul ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

BIOLOGICAL ACTIVITY; CLINICAL STUDY; HUMAN; INTESTINE MUCOSA; NONHUMAN; PEPTIDE ANALYSIS; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCIENCE; SHORT BOWEL SYNDROME; AGONISTS; ANIMAL; DRUG DEVELOPMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; SHORT BOWEL SYNDROME; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85037081793     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI97233     Document Type: Review

References (100)

1. Drucker DJ. Evolving concepts and translational relevance of enteroendocrine cell biology. JClin EndocrinolMetab. 2016;101(3):778–786.
2. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. Can J Biochem. 1971;49(8):867–872.
3. Lund PK, Goodman RH, Dee PC, HabenerJF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci U S A. 1982;79(2):345–349.
4. Lund PK, Goodman RH, Habener JF. Pancreatic pre-proglucagons are encoded by two separate mRNAs. JBiolChem. 1981;256(13):6515–6518.
5. Lund PK, Goodman RH, Montminy MR, Dee PC, Habener JF. Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA. JBiolChem. 1983;258(5):3280–3284.
6. Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. JBiol Chem. 1984;259(22):14082–14087.
7. Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF. Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. Endocrinology. 1984;115(6):2176–2181.
8. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304(5924):368–371.
9. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302(5910):716–718.
10. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF. Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci U S A. 1983;80(18):5485–5489.
11. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37(5):826–828.
12. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876–913.
13. Steiner DF. The proprotein convertases. Curr Opin Chem Biol. 1998;2(1):31–39.
14. Kumar D, Mains RE, Eipper BA. 60 YEARS OF POMC: From POMC and α-MSH to PAM, molecular oxygen, copper, and vitamin C. J Mol Endocrinol. 2016;56(4):T63–T76.
15. Drucker DJ, Mojsov S, Habener JF. Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. JBiolChem. 1986;261(21):9637–9643.
16. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. JBiolChem. 1986;261(25):11880–11889.
17. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467–1475.
18. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia. 1987;30(11):874–881.
19. Patzelt C, Schiltz E. Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci U S A. 1984;81(16):5007–5011.
20. Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990;265(14):8001–8008.
21. Hoosein NM, Gurd RS. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase. FEBSLett. 1984;178(1):83–86.
22. Ghiglione M, Uttenthal LO, George SK, Bloom SR. How glucagon-like is glucagon-like peptide-1? Diabetologia. 1984;27(6):599–600.
23. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84(10):3434–3438.
24. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616–619.
25. Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBSLett. 1987;211(2):169–174.
26. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300–1304.
27. Holst JJ, Hending LG, Rehfeld JF. Gut glucagon and reactive hypoglycaemia. Lancet. 1973;1(7810):1008.
28. Heding LG. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia. 1971;7(1):10–19.
29. Holst JJ. Extrapancreatic glucagons. Digestion. 1978;17(2):168–190.
30. Holst JJ. Gut glucagon, enteroglucagon, gut glu-cagonlike immunoreactivity, glicentin — current status. Gastroenterology. 1983;84(6):1602–1613.
31. Holst JJ. Evidence that glicentin contains the entire sequence of glucagon. Biochem J. 1980;187(2):337–343.
32. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J. 1982;207(3):381–388.
33. Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature. 1981;289(5797):514–516.
34. Patzelt C, Schug G. The major proglucagon fragment: an abundant islet protein and secretory product. FEBSLett. 1981;129(1):127–130.
35. Orskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. JBiolChem. 1989;264(22):12826–12829.
36. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metab Clin Exp. 1987;36(7):677–682.
37. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009–2013.
38. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metab Clin Exp. 1994;43(1):104–108.
39. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–673.
40. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
41. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hypergly-caemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744.
42. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharma-cokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Diabetologia. 1995;38(6):720–725.
43. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. JClinEndocrinolMetab. 1995;80(3):952–957.
44. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131.
45. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 1998;41(3):271–278.
46. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998;47(5):764–769.
47. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47(11):1663–1670.
48. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–830.
49. Drucker DJ, Philippe J, Jepeal L, Habener JF. Glucagon gene 5’-flanking sequences promote islet cell-specific gene transcription. JBiolChem. 1987;262(32):15659–15665.
50. Philippe J, Drucker DJ, Knepel W, Jepeal L, Misulo-vin Z, Habener JF. Alpha-cell-specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins. MolCellBiol. 1988;8(11):4877–4888.
51. Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. JBiolChem. 1988;263(27):13475–13478.
52. Drucker DJ, Brubaker PL. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci U S A. 1989;86(11):3953–3957.
53. Lee YC, Asa SL, Drucker DJ. Glucagon gene 5′-flanking sequences direct expression of SV40 large T antigen to the intestine producing carcinoma of the large bowel in transgenic mice. JBiolChem. 1992;267(15):10705–10708.
54. Drucker DJ, Lee YC, Asa SL, Brubaker PL. Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUTag transplantable tumor. MolEndocrinol. 1992;6(12):2175–2184.
55. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. MolEndocrinol. 1994;8(12):1646–1655.
56. Brubaker PL, Schloos J, Drucker DJ. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology. 1998;139(10):4108–4114.
57. Ehrlich P, Tucker D, Asa SL, Brubaker PL, Drucker DJ. Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. Am J Physiol. 1994; 267(5 pt 1):E662–E671.
58. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911–7916.
59. Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. JBiolChem. 1988;263(18):8621–8624.
60. Drucker DJ, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15(7):673–677.
61. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001;61(2):687–693.
62. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol. 1999; 276(1 pt 1):G79–G91.
63. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277(5 pt 1):E937–E947.
64. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997;272(6 pt 1):E1050–E1058.
65. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5 pt 1):G911–G921.
66. Jeppesen PB, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806–815.
67. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561–583.
68. Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481.e3.
69. Scrocchi LA, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996;2(11):1254–1258.
70. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. JBiolChem. 2003;278(1):471–478.
71. Yusta B, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4(5):391–406.
72. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. JBiolChem. 1992;267(11):7402–7405.
73. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. JBiol Chem. 1997;272(7):4108–4115.
74. Drucker DJ, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
75. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. CellMetab. 2016;24(1):15–30.
76. Fujita H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579–589.
77. Koehler JA, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. CellMetab. 2015;21(3):379–391.
78. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350.
79. Pujadas G, Drucker DJ. Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical relevance. Endocr Rev. 2016;37(6):554–583.
80. Noyan-Ashraf MH, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–983.
81. Kim M, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–575.
82. Yusta B, et al. GLP-1 receptor (GLP-1R) agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte (IEL) GLP-1R. Diabetes. 2015;64(7):2537–2549.
83. Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
84. Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239.
85. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEngl JMed. 2016;375(19):1834–1844.
86. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
87. Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017;40(7):821–831.
88. Bak MJ, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab. 2014;16(11):1155–1164.
89. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21(1):73–80.
90. Panjwani N, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(–/–) mice. Endocrinology. 2013;154(1):127–139.
91. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. CellMetab. 2008;8(6):532–539.
92. Petersen N, et al. Generation of L cells in mouse and human small intestine organoids. Diabetes. 2014;63(2):410–420.
93. Athauda D, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial [published online ahead of print August 3, 2017]. Lancet. https://doi.org/10.1016/S01406736(17)31585-4.
94. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470.
95. Finan B, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36.
96. Tschöp MH, et al. Unimolecular polypharma-cy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51–62.
97. Serre V, Dolci W, Scrocchi LA, Drucker DJ, Efrat S, Thorens B. Exendin-(9-39) as an inverse agonist of the murine GLP-1 receptor. Endocrinology. 1998;139(11):4448–4454.
98. Salehi M, Gastaldelli A, D’Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. 2014;146(3):669–680.e2.
99. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2(2):152–164.
100. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62(10):3316–3323.